Molecular_JJ Epidemiology_NN of_IN Erythromycin_NP Resistance_NP in_IN Streptococcus_NP pneumoniae_NP Isolates_NP from_IN Blood_NP and_CC Noninvasive_NP Sites_NP Erythromycin-resistant_NP isolates_VBZ of_IN Streptococcus_NP pneumoniae_NNS from_IN blood_NN cultures_NNS and_CC noninvasive_JJ sites_NNS were_VBD studied_VBN over_IN a_DT 3-year_JJ period_NN ._SENT The_DT prevalence_NN of_IN erythromycin_NN resistance_NN was_VBD 11.9_CD %_NN (_( 19_CD of_IN 160_CD )_) in_IN blood_NN culture_NN isolates_NNS but_CC 4.2_CD %_NN (_( 60_CD of_IN 1,435_CD )_) in_IN noninvasive-site_JJ isolates_NNS ._SENT Sixty-two_NN of_IN the_DT 79_CD resistant_JJ isolates_NNS were_VBD available_JJ for_IN study_NN ._SENT The_DT M_NP phenotype_NN was_VBD responsible_JJ for_IN 76_CD %_NN (_( 47_CD of_IN 62_CD )_) of_IN resistance_NN ,_, largely_RB due_JJ to_TO a_DT serotype_NN 14_CD clone_NN ,_, characterized_VBN by_IN multilocus_NN sequence_NN typing_VBG as_IN ST9_NP ,_, which_WDT accounted_VBD for_IN 79_CD %_NN (_( 37_CD of_IN 47_CD )_) of_IN M_NP phenotype_NN resistance_NN ._SENT The_DT ST9_NP clone_NN was_VBD 4.8_CD times_NNS more_RBR common_JJ in_IN blood_NN than_IN in_IN noninvasive_JJ sites_NNS ._SENT All_DT M_NP phenotype_NN isolates_NNS were_VBD PCR_NP positive_JJ for_IN mef(A)_NN ,_, but_CC sequencing_NP revealed_VBD that_IN the_DT ST9_NP clone_NN possessed_VBD the_DT mef(A)_JJ sequence_NN commonly_RB associated_VBN with_IN Streptococcus_NP pyogenes_NNS ._SENT All_DT M_NP phenotype_NN isolates_VBZ with_IN this_DT mef(A)_JJ sequence_NN also_RB had_VBD sequences_NNS consistent_JJ with_IN the_DT presence_NN of_IN the_DT Tn1207.1_JJ genetic_JJ element_NN inserted_VBN in_IN the_DT celB_NN gene_NN ._SENT In_IN contrast_NN ,_, isolates_VBZ with_IN the_DT mef(E)_JJ sequence_NN normally_RB associated_VBN with_IN S._NP pneumoniae_NNS contained_VBD sequences_NNS consistent_JJ with_IN the_DT presence_NN of_IN the_DT mega_JJ insertion_NN element_NN ._SENT All_DT MLSB_NP isolates_NNS carried_VBD erm(B)_NN ,_, and_CC two_CD isolates_NNS carried_VBD both_DT erm(B)_NN and_CC mef(E_NNS )_) ._SENT Fourteen_NN of_IN the_DT 15_CD MLSB_NP isolates_NNS were_VBD tetracycline_NN resistant_JJ and_CC contained_VBN tet(M_NN )_) ._SENT However_RB ,_, six_CD M_NP phenotype_NN isolates_VBZ of_IN serotypes_NNS 19_CD (_( two_CD isolates_NNS )_) and_CC 23_CD (_( four_CD isolates_NNS )_) were_VBD also_RB tetracycline_NN resistant_NN and_CC contained_VBN tet(M_NN )_) ._SENT MICs_NNS for_IN isolates_NNS with_IN the_DT mef(A)_JJ sequence_NN were_VBD significantly_RB higher_JJR than_IN MICs_NP for_IN isolates_NNS with_IN the_DT mef(E)_JJ sequence_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT Thus_RB ,_, the_DT ST9_NP clone_NN of_IN S._NP pneumoniae_NNS is_VBZ a_DT significant_JJ cause_NN of_IN invasive_JJ pneumococcal_JJ disease_NN in_IN northeast_JJ Scotland_NP and_CC is_VBZ the_DT single_JJ most_RBS important_JJ contributor_NN to_TO M_NP phenotype_NN erythromycin_NN resistance_NN ._SENT There_EX are_VBP two_CD commonly_RB described_VBN mechanisms_NNS of_IN erythromycin_NN resistance_NN :_: active_JJ drug_NN efflux_NN and_CC methylation_NN of_IN the_DT antibiotic_JJ target_NN site_NN ._SENT In_IN Streptococcus_NP pneumoniae_NNS these_DT result_NN in_IN two_CD major_JJ phenotypes_NNS ,_, M_NP and_CC MLSB_NP ._SENT M_NP phenotype_NN isolates_NNS are_VBP resistant_JJ to_TO macrolides_NNS via_IN an_DT active_JJ efflux_NN mechanism_NN that_WDT requires_VBZ the_DT presence_NN of_IN the_DT mef(A)_JJ gene_NN ._SENT This_DT gene_NN was_VBD first_RB identified_VBN in_IN Streptococcus_NP pyogenes_NNS and_CC originally_RB designated_VBN mef(A)_NN ,_, while_IN a_DT similar_JJ gene_NN with_IN 90_CD %_NN identity_NN to_TO mef(A)_NN was_VBD later_RBR identified_VBN in_IN S._NP pneumoniae_NNS and_CC designated_VBN mef(E)_NN ._SENT More_RBR recently_RB ,_, it_PP has_VBZ been_VBN proposed_VBN that_IN these_DT two_CD genes_NNS are_VBP members_NNS of_IN the_DT same_JJ family_NN and_CC should_MD be_VB referred_VBN to_TO by_IN the_DT generic_JJ label_NN of_IN mef(A)_NN ._SENT The_DT product_NN of_IN the_DT mef(A)_JJ gene_NN has_VBZ not_RB been_VBN directly_RB characterized_VBN ,_, but_CC its_PP$ predicted_VBN amino_NN acid_NN sequence_NN shows_VBZ homology_NN with_IN other_JJ transporter_NN proteins_NNS ._SENT Santagati_NP et_FW al._FW described_VBN ,_, in_IN a_DT clinical_JJ isolate_NN of_IN S._NP pneumoniae_NNS ,_, a_DT 7.244-kb_JJ chromosomal_JJ element_NN ,_, Tn1207.1_NN that_WDT contained_VBD 8_CD open_JJ reading_NN frames_NNS (_( ORFs_NP )_) ,_, one_CD of_IN which_WDT (_( ORF4_NP )_) was_VBD 100_CD %_NN identical_JJ to_TO the_DT original_JJ mef(A)_NN sequence_NN of_IN S._NP pyogenes_NNS ._SENT Downstream_RB from_IN mef(A)_NN ,_, ORF5_NP coded_VBD for_IN a_DT protein_NN that_WDT showed_VBD homology_NN to_TO MsrA_NP ,_, an_DT ATP-binding_NP protein_NN that_WDT mediates_VBZ resistance_NN to_TO macrolides_NNS and_CC streptogramin_NN B_NN in_IN staphylococci_NNS ._SENT Upstream_RB from_IN mef(A)_NN ,_, ORF2_NP was_VBD thought_VBN to_TO represent_VB an_DT integrase_NN or_CC site-specific_JJ recombinase_NN ,_, although_IN Tn1207.1_NP was_VBD considered_VBN a_DT defective_JJ transposon_NN because_IN it_PP terminates_VBZ at_IN the_DT 3_CD '_POS end_NN in_IN a_DT truncated_JJ ORF_NP ._SENT In_IN the_DT isolate_NN studied_VBD ,_, Tn1207.1_NP was_VBD inserted_VBN in_IN the_DT pneumococcal_JJ genome_NN within_IN the_DT competence_NN gene_NN celB_NN ._SENT A_DT further_JJR 5.4-_CD or_CC 5.5-kb_JJ chromosomal_JJ insertion_NN element_NN has_VBZ recently_RB been_VBN described_VBN by_IN Gay_NP and_CC Stephens_NP and_CC has_VBZ been_VBN designated_VBN the_DT macrolide_NN efflux_NN genetic_JJ assembly_NN (_( mega_JJ )_) ._SENT mega_JJ contains_VBZ 5_CD ORFs_NNS ,_, of_IN which_WDT ORF1_NP is_VBZ identical_JJ to_TO the_DT original_JJ mef(E)_NN sequence_NN of_IN S._NP pneumoniae_NNS ._SENT As_RB with_IN Tn1207.1_NP ,_, there_EX is_VBZ also_RB a_DT homologue_NN of_IN the_DT msr(A)_JJ gene_NN downstream_JJ from_IN mef(E)_JJ designated_VBN mel_NN ,_, after_IN the_DT first_JJ three_CD amino_NN acids_NNS of_IN the_DT predicted_VBN protein_NN ._SENT The_DT sequences_NNS of_IN the_DT two_CD msr(A)_JJ homologues_NNS found_VBN in_IN Tn1207.1_NP and_CC mega_JJ are_VBP 98_CD %_NN identical_JJ ._SENT The_DT five_CD ORFs_NNS of_IN mega_JJ show_NN a_DT high_JJ degree_NN of_IN identity_NN with_IN ORFs_NP 4_CD to_TO 8_CD of_IN Tn1207.1_NP ,_, but_CC mega_JJ does_NNS not_RB contain_VBP ORFs_NNS with_IN integrase_NN or_CC recombinase_NN homology_NN ._SENT PCR_NP studies_NNS on_IN 89_CD mef(E)-positive_JJ clinical_JJ isolates_NNS from_IN Atlanta_NP revealed_VBD that_IN there_EX are_VBP more_JJR than_IN four_CD different_JJ insertion_NN sites_NNS for_IN mega_JJ in_IN the_DT pneumococcal_JJ genome_NN ._SENT None_NN of_IN the_DT four_CD insertion_NN sites_NNS identified_VBN were_VBD in_IN the_DT celB_NN gene_NN ._SENT In_IN the_DT MLSB_NP phenotype_NN ,_, resistance_NN to_TO the_DT structurally_RB unrelated_JJ macrolide_NN ,_, lincosamide_NN ,_, and_CC streptogramin_NP B_NP antibiotics_NNS is_VBZ brought_VBN about_RB by_IN methylation_NN of_IN 23S_JJ rRNA_NN ,_, the_DT common_JJ target_NN of_IN these_DT agents_NNS ._SENT MLSB_NN resistance_NN is_VBZ determined_VBN by_IN members_NNS of_IN the_DT erm_JJ gene_NN family_NN ,_, and_CC in_IN S._NP pneumoniae_NNS the_DT erm(B)_NN gene_NN is_VBZ usually_RB carried_VBN on_IN the_DT 25.3-kb_JJ conjugative_JJ transposon_NN Tn1545_NP along_IN with_IN a_DT separate_JJ gene_NN ,_, tet(M)_NN ,_, that_WDT codes_VBZ for_IN tetracycline_NN resistance_NN ._SENT Transfer_NN of_IN Tn1545_NP between_IN strains_NNS is_VBZ mediated_VBN by_IN the_DT excisionase_NN (_( xis_NNS )_) and_CC integrase_JJ (_( int_JJ )_) genes_NNS ._SENT Other_JJ transposable_JJ elements_NNS such_JJ as_IN Tn917-like_JJ elements_NNS and_CC the_DT composite_JJ transposon-like_JJ structure_NN Tn3872_NP can_MD also_RB carry_VB erm(B)_NN in_IN S._NP pneumoniae_NNS ._SENT The_DT prevalence_NN of_IN erythromycin_NN resistance_NN in_IN S._NP pneumoniae_NNS has_VBZ increased_VBN in_IN several_JJ countries_NNS over_IN the_DT past_JJ few_JJ years_NNS ._SENT However_RB ,_, there_EX are_VBP considerable_JJ differences_NNS between_IN countries_NNS in_IN the_DT relative_JJ contributions_NNS of_IN the_DT M_NP and_CC MLSB_NP phenotypes_NNS to_TO the_DT overall_JJ prevalence_NN of_IN resistance_NN ._SENT Surveys_NNS in_IN the_DT United_NP States_NPS show_VBP a_DT predominance_NN of_IN the_DT M_NP phenotype_NN ,_, while_IN in_IN Italy_NP ,_, Belgium_NP ,_, and_CC Germany_NP the_DT MLSB_NP phenotype_NN is_VBZ more_RBR common_JJ ._SENT A_DT survey_NN of_IN S._NP pneumoniae_NNS bacteremia_NN carried_VBD out_RP in_IN our_PP$ laboratory_NN showed_VBD that_IN the_DT prevalence_NN of_IN erythromycin-resistant_JJ isolates_NNS was_VBD 12_CD %_NN and_CC that_IN 75_CD %_NN of_IN these_DT isolates_NNS had_VBD the_DT M_NP phenotype_NN ._SENT All_DT of_IN the_DT M_NP phenotype_NN isolates_NNS belonged_VBD to_TO serotype_VB 14_CD and_CC had_VBD very_RB similar_JJ profiles_NNS on_IN pulsed-field_JJ gel_NN electrophoresis_NN ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO compare_VB the_DT prevalence_NN of_IN the_DT two_CD major_JJ erythromycin_NN resistance_NN phenotypes_NNS in_IN pneumococcal_JJ isolates_NNS from_IN blood_NN and_CC from_IN noninvasive_JJ sites_NNS ._SENT We_PP serotyped_VBD all_DT erythromycin-resistant_JJ isolates_NNS and_CC identified_VBD the_DT resistance_NN genes_NNS and_CC associated_VBN insertion_NN elements_NNS by_IN PCR_NP and_CC sequencing_NP ._SENT Bacterial_JJ isolates_NNS ._SENT |_SYM All_DT bacterial_JJ isolates_NNS ,_, unless_IN otherwise_RB stated_VBN ,_, were_VBD cultured_VBN from_IN clinical_JJ specimens_NNS submitted_VBN to_TO the_DT routine_JJ diagnostic_JJ laboratories_NNS of_IN the_DT Department_NP of_IN Medical_NP Microbiology_NP ,_, University_NP of_IN Aberdeen_NP ,_, Aberdeen_NP ,_, United_NP Kingdom_NP ._SENT Over_IN a_DT 3-year_JJ period_NN ,_, from_IN 1998_CD to_TO 2000_CD ,_, all_DT blood_NN culture_NN isolates_VBZ of_IN S._NP pneumoniae_NNS and_CC all_DT erythromycin-resistant_NN isolates_VBZ from_IN other_JJ sites_NNS were_VBD collected_VBN ._SENT S._NP pneumoniae_NNS was_VBD identified_VBN by_IN alpha-hemolysis_NN on_IN blood_NN agar_NN and_CC sensitivity_NN to_TO optochin_NN ,_, and_CC erythromycin_NN resistance_NN was_VBD detected_VBN in_IN the_DT first_JJ instance_NN by_IN disk_NN diffusion_NN ._SENT Isolates_NNS were_VBD serotyped_VBN by_IN the_DT Scottish_NP Pneumococcal_NP Reference_NP Laboratory_NP ,_, Stobhill_NP Hospital_NP ,_, Glasgow_NP ,_, United_NP Kingdom_NP ,_, by_IN coagglutination_NN ;_: selected_VBN isolates_NNS were_VBD also_RB characterized_VBN by_IN multilocus_NN sequence_NN typing_VBG (_( MLST_NP )_) by_IN the_DT same_JJ laboratory_NN ._SENT Isolates_NNS from_IN sites_NNS other_JJ than_IN blood_NN ,_, designated_VBN noninvasive_JJ ,_, were_VBD obtained_VBN from_IN the_DT upper_JJ respiratory_JJ tract_NN ,_, sputum_NN ,_, eye_NN swabs_NNS ,_, and_CC ear_NN swabs_NNS ._SENT We_PP obtained_VBD details_NNS on_IN all_DT pneumococci_NNS isolated_VBN during_IN the_DT study_NN period_NN from_IN the_DT computer_NN database_NN of_IN our_PP$ diagnostic_JJ laboratory_NN and_CC thus_RB obtained_VBN baseline_JJ figures_NNS for_IN the_DT number_NN of_IN isolates_NNS from_IN sites_NNS other_JJ than_IN blood_NN ._SENT A_DT small_JJ number_NN of_IN isolates_NNS from_IN invasive_JJ sites_NNS other_JJ than_IN blood_NN ,_, e.g._FW ,_, cerebrospinal_JJ fluid_NN ,_, were_VBD excluded_VBN ,_, and_CC duplicate_JJ isolates_NNS from_IN the_DT same_JJ episode_NN of_IN infection_NN in_IN any_DT one_CD patient_NN were_VBD counted_VBN only_RB once_RB ._SENT Three_CD S._NP pneumoniae_NNS M_NP phenotype_NN isolates_VBZ (_( serotype_NN 14_CD )_) from_IN the_DT South_NP of_IN England_NP (_( M44_NP ,_, M47_JJ ,_, and_CC M58_NP )_) ,_, two_CD from_IN Australia_NP (_( M231_NP and_CC M238_NP )_) ,_, and_CC one_CD from_IN Belgium_NP (_( M27_NP )_) were_VBD kindly_RB supplied_VBN by_IN M._NP C._NP Enright_NP and_CC B._NP G._NP Spratt_NP ,_, Wellcome_NP Trust_NP Centre_NP for_IN the_DT Epidemiology_NN of_IN Infectious_NP Disease_NP ,_, Department_NP of_IN Zoology_NP ,_, Oxford_NP University_NP ,_, Oxford_NP ,_, United_NP Kingdom_NP ._SENT Three_CD susceptible_JJ isolates_NNS (_( serotype_NN 14_CD )_) from_IN Australia_NP (_( M222_NP ,_, M229_NP ,_, and_CC M237_JJ )_) were_VBD also_RB obtained_VBN from_IN the_DT same_JJ source_NN ._SENT The_DT isolates_NNS donated_VBN are_VBP all_RB listed_VBN in_IN the_DT MLST_NP database_NN as_IN sequence_NN type_NN 9_CD (_( ST9_NP )_) ._SENT Isolates_NNS were_VBD stored_VBN at_IN -70C_NN in_IN Protect_NP (_( TSC_NP Ltd._NP ,_, Heywood_NP ,_, United_NP Kingdom_NP )_) and_CC recovered_VBD when_WRB required_VBN by_IN culture_NN on_IN blood_NN agar_NN plates_NNS at_IN 37C_JJ in_IN air_NN with_IN 5_CD %_NN CO2_NN ._SENT Resistance_NN to_TO erythromycin_NN and_CC the_DT resistance_NN phenotype_NN were_VBD confirmed_VBN by_IN disk_NN diffusion_NN assay_NN with_IN the_DT disks_NNS adjacent_JJ to_TO detect_VB inducible_JJ resistance_NN ._SENT Erythromycin_NN MICs_NNS were_VBD determined_VBN by_IN E-test_NN (_( AB_NP Biodisk_NP ,_, Solna_NP ,_, Sweden_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._SENT S._NP pneumoniae_NNS strain_VBP ATCC_NP 49619_CD was_VBD tested_VBN simultaneously_RB as_IN a_DT quality_NN control_NN ,_, and_CC the_DT MIC_NN for_IN this_DT strain_NN was_VBD within_IN the_DT manufacturer_NN 's_POS recommended_JJ range_NN ._SENT MICs_NNS were_VBD also_RB determined_VBN by_IN broth_NN microdilution_NN according_VBG to_TO the_DT guidelines_NNS of_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) ,_, except_IN that_DT additional_JJ antibiotic_JJ concentrations_NNS of_IN 3_CD ,_, 6_CD ,_, 12_CD ,_, and_CC 24_CD mg/liter_NN were_VBD added_VBN to_TO the_DT recommended_JJ test_NN range_NN ._SENT PCR_NP ._SENT |_SYM S._NP pneumoniae_NNS cells_NNS were_VBD harvested_VBN from_IN one_CD confluent_JJ blood_NN agar_NN plate_NN ._SENT Chromosomal_JJ DNA_NN was_VBD extracted_VBN from_IN cell_NN suspensions_NNS by_IN the_DT method_NN of_IN Pitcher_NN et_FW al._FW or_CC with_IN a_DT DNA_NP extraction_NN kit_NN for_IN gram-positive_JJ bacteria_NNS (_( Puregene_NP ;_: Gentra_NP Systems_NPS ,_, Minneapolis_NP ,_, Minn._NP )_) ._SENT The_DT mef(A)_JJ gene_NN was_VBD amplified_VBN by_IN using_VBG primers_NNS based_VBN on_IN the_DT published_VBN sequence_NN of_IN S._NP pyogenes_NNS (_( 5_CD '_POS ATGGAAAAATACAACAATTG_NP [_SYM forward_RB ]_SYM and_CC 5_CD '_'' TTATTTTAAATCTAATTTTCTAAC_NP [_SYM reverse_NN ]_SYM )_) ._SENT PCR_NP conditions_NNS for_IN amplification_NN of_IN the_DT mef(A)_JJ gene_NN comprised_VBD an_DT initial_JJ denaturation_NN step_NN at_IN 94C_NN for_IN 4_CD min_NN ,_, followed_VBN by_IN 35_CD cycles_NNS of_IN denaturation_NN at_IN 94C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 50C_NN for_IN 30_CD s_NNS ,_, and_CC elongation_NN at_IN 72C_NP for_IN 30_CD s._NN After_IN the_DT amplification_NN cycles_NNS ,_, a_DT final_JJ elongation_NN step_NN at_IN 72C_NP for_IN 5_CD min_NN was_VBD carried_VBN out_RP ._SENT The_DT primer_NN set_NN used_VBN to_TO amplify_VB the_DT erm(B)_JJ gene_NN was_VBD based_VBN on_IN the_DT erythromycin_NN resistance_NN gene_NN carried_VBN in_IN the_DT conjugative_JJ transposon_NP Tn1545_NP from_IN S._NP pneumoniae_NNS and_CC consisted_VBN of_IN 5_CD '_POS ATTGGAACAGGTAAAGGGC_NP (_( forward_RB )_) and_CC 5_CD '_POS GAACATCTGTGGTATGGCG_NP (_( reverse_NN )_) ._SENT PCR_NP conditions_NNS for_IN amplification_NN of_IN the_DT erm(B)_JJ gene_NN comprised_VBD an_DT initial_JJ denaturation_NN step_NN at_IN 94C_NN for_IN 4_CD min_NN ,_, followed_VBN by_IN 30_CD cycles_NNS of_IN denaturation_NN at_IN 94C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 57C_NN for_IN 30_CD s_NNS ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN ._SENT After_IN the_DT amplification_NN cycles_NNS ,_, a_DT final_JJ elongation_NN step_NN was_VBD performed_VBN at_IN 72C_NP for_IN 7_CD min_NN ._SENT The_DT homologue_NN of_IN msr(A)_NN was_VBD amplified_VBN by_IN using_VBG primers_NNS based_VBN on_IN the_DT sequence_NN of_IN this_DT gene_NN contained_VBN in_IN the_DT transposable_JJ element_NN Tn1207.1_NP of_IN S._NP pneumoniae_NP (_( GenBank_NP accession_NN number_NN )_) ,_, 5_CD '_POS TGCCTATATTCCCCAGTT_NP (_( forward_RB )_) and_CC 5_CD '_POS TTAATTTCCGCACCGACTA_NP (_( reverse_NN )_) ._SENT PCR_NP conditions_NNS for_IN amplification_NN of_IN the_DT msr(A)_JJ homologue_NN comprised_VBD an_DT initial_JJ denaturation_NN step_NN at_IN 94C_NN for_IN 4_CD min_NN ,_, followed_VBN by_IN 30_CD cycles_NNS of_IN denaturation_NN at_IN 94C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 50C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN ._SENT After_IN the_DT amplification_NN cycles_NNS ,_, a_DT final_JJ elongation_NN step_NN at_IN 72C_NP for_IN 10_CD min_NN was_VBD carried_VBN out_RP ._SENT To_TO establish_VB whether_IN the_DT transposable_JJ element_NN carrying_VBG mef(A)_NN in_IN our_PP$ isolates_NNS had_VBD the_DT same_JJ insertion_NN site_NN as_IN Tn1207.1_NP ,_, specific_JJ PCR_NP primers_NNS were_VBD designed_VBN ._SENT The_DT forward_JJ primer_NN ,_, 5_CD '_'' CTTTCCTTTCTCTATCCA_NP ,_, lies_VBZ upstream_RB of_IN the_DT known_VBN insertion_NN site_NN of_IN Tn1207.1_NP in_IN the_DT celB_NN gene_NN (_( GenBank_NP accession_NN number_NN )_) ._SENT The_DT reverse_JJ primer_NN ,_, 5_CD '_'' TACATCAACATTACCATCTG_NP ,_, was_VBD based_VBN on_IN the_DT 5'-end_JJ sequence_NN of_IN Tn1207.1_NP (_( GenBank_NP accession_NN number_NN )_) ._SENT Amplification_NN conditions_NNS were_VBD the_DT same_JJ as_RB for_IN the_DT msr(A)_JJ homologue_NN ._SENT Primers_NNS for_IN the_DT tet(M)_NN (_( 5_CD '_POS AGTTTTAGCTCATGTTGATG_NP [_SYM forward_RB ]_SYM and_CC 5_CD '_'' TCCGACTATTTGGACGACGG_NP [_SYM reverse_NN ]_SYM )_) and_CC int_NNS (_( 5_CD '_POS GCGTGATTGTATCTCACT_NP [_SYM forward_RB ]_SYM and_CC 5_CD '_'' GACCTCCTGTTGCTTCT_NP [_SYM reverse_NN ]_SYM )_) genes_NNS were_VBD as_RB described_VBN by_IN Doherty_NP et_FW al._FW ._SENT Primers_NNS for_IN the_DT xis_NNS gene_NN ,_, 5_LS '_POS AAGCAGACTGACATTCCTA_NP (_( forward_RB )_) and_CC 5_CD '_POS GCGTCCAATGTATCTATAA_NP (_( reverse_NN )_) ,_, were_VBD based_VBN on_IN the_DT sequence_NN of_IN this_DT gene_NN available_JJ in_IN the_DT database_NN (_( GenBank_NP accession_NN number_NN )_) ._SENT PCR_NP conditions_NNS for_IN amplification_NN of_IN tet(M)_NN comprised_VBD an_DT initial_JJ denaturation_NN step_NN at_IN 94C_NN for_IN 4_CD min_NN ,_, followed_VBN by_IN 35_CD cycles_NNS of_IN denaturation_NN at_IN 94C_NN for_IN 30_CD s_NNS ,_, annealing_VBG at_IN 55C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN ,_, 30_CD s._NN After_IN the_DT amplification_NN cycles_NNS ,_, a_DT final_JJ elongation_NN step_NN at_IN 72C_NP for_IN 10_CD min_NN was_VBD carried_VBN out_RP ._SENT Conditions_NNS for_IN amplification_NN of_IN int_NNS and_CC xis_NNS were_VBD the_DT same_JJ as_IN those_DT used_VBN for_IN the_DT msr(A)_JJ homologue_NN ._SENT All_DT PCR_NP amplification_NN mixtures_NNS contained_VBD 100_CD ng_NNS of_IN genomic_JJ DNA_NN ,_, forward_JJ and_CC reverse_JJ primers_NNS (_( 250_CD nM_NN )_) ,_, MgCl2_NP (_( 1.5_CD mM_NNS )_) ,_, deoxynucleoside_NN triphosphates_NNS (_( 200_CD muM_NN ;_: Amersham_NP Pharmacia_NP Biotech_NP UK_NP Ltd._NP ,_, Little_NP Chalfont_NP ,_, United_NP Kingdom_NP )_) ,_, and_CC Taq_NP polymerase_NN (_( 5_CD U_NP )_) plus_CC buffer_VB (_( Bioline_NP ,_, London_NP ,_, United_NP Kingdom_NP )_) ._SENT PCR_NP was_VBD performed_VBN on_IN a_DT Perkin-Elmer_NP (_( PE_NP )_) Biosystems_NP (_( Warrington_NP ,_, United_NP Kingdom_NP )_) 9700_NP Thermocycler_NP ._SENT PCR_NP products_NNS were_VBD detected_VBN by_IN electrophoresis_NN on_IN agarose_JJ gels_NNS ,_, followed_VBN by_IN staining_VBG with_IN ethidium_NN bromide_NN and_CC UV_NP transillumination_NN ._SENT DNA_NP sequence_NN analysis_NN ._SENT |_SYM PCR_NP amplification_NN products_NNS were_VBD purified_VBN by_IN using_VBG Centricon_NP C100_NP columns_NNS (_( Millipore_NP UK_NP Ltd._NP ,_, Watford_NP ,_, United_NP Kingdom_NP )_) ._SENT Purified_VBN PCR_NP products_NNS were_VBD sequenced_JJ by_IN using_VBG the_DT corresponding_JJ amplification_NN primers_NNS ._SENT In_IN addition_NN ,_, a_DT specific_JJ region_NN of_IN interest_NN within_IN the_DT tet(M)_JJ gene_NN was_VBD sequenced_VBN in_IN both_DT directions_NNS by_IN using_VBG internal_JJ sequencing_NP primers_NNS 5_CD '_POS CGAACTTTACCGAATCTGAA_NP (_( forward_RB )_) and_CC 5_CD '_POS CAACGGAAGCGGTGATACAG_NP (_( reverse_NN )_) ;_: these_DT were_VBD based_VBN on_IN the_DT published_VBN sequence_NN of_IN tet(M)_NN (_( GenBank_NP accession_NN number_NN )_) ._SENT Sequencing_NP reactions_NNS were_VBD performed_VBN by_IN using_VBG the_DT BigDye_NP Terminator_NN cycle_NN sequencing_VBG kit_NN (_( PE_NP Biosystems_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Sequencing_NP products_NNS were_VBD run_VBN on_IN an_DT ABI_NP 377_CD automated_JJ DNA_NN sequencer_NN ,_, and_CC sequencing_VBG analysis_NN was_VBD carried_VBN out_RP with_IN the_DT SeqEd_JJ 1.0.3_CD DNA_NN analysis_NN program_NN (_( PE_NP Biosystems_NP )_) ._SENT Statistical_JJ analysis_NN ._SENT |_SYM The_DT significance_NN of_IN differences_NNS in_IN the_DT distribution_NN of_IN isolates_NNS between_IN blood_NN and_CC noninvasive_JJ sites_NNS was_VBD determined_VBN by_IN the_DT chi-square_NN test_NN ,_, and_CC the_DT significance_NN of_IN differences_NNS between_IN erythromycin_NN MICs_NNS was_VBD determined_VBN by_IN the_DT Mann-Whitney_NP test_NN ._SENT Both_DT tests_NNS were_VBD performed_VBN with_IN the_DT SPSS_NP statistical_JJ package_NN ._SENT Erythromycin_NN resistance_NN in_IN S._NP pneumoniae_NNS isolates_VBZ from_IN blood_NN and_CC noninvasive_JJ sites_NNS ._SENT |_SYM Over_IN the_DT 3-year_JJ study_NN period_NN ,_, there_EX were_VBD 160_CD isolates_NNS of_IN S._NP pneumoniae_NNS from_IN blood_NN and_CC 1,435_CD from_IN other_JJ sites_NNS ._SENT Nineteen_CD blood_NN isolates_NNS (_( 11.9_CD %_NN )_) were_VBD erythromycin_NN resistant_JJ ,_, and_CC 18_CD of_IN these_DT were_VBD available_JJ for_IN confirmation_NN of_IN phenotype_NN and_CC further_JJR study_NN ._SENT The_DT prevalence_NN of_IN erythromycin_NN resistance_NN was_VBD much_RB lower_JJR in_IN isolates_NNS from_IN noninvasive_JJ sites_NNS ._SENT Sixty_CD of_IN the_DT 1,435_CD isolates_NNS (_( 4.2_CD %_NN )_) were_VBD erythromycin_NN resistant_JJ ,_, and_CC 44_CD of_IN these_DT were_VBD available_JJ for_IN confirmation_NN of_IN phenotype_NN and_CC further_JJR study_NN ._SENT The_DT distribution_NN of_IN resistance_NN phenotypes_NNS and_CC serotypes_NNS among_IN available_JJ isolates_NNS from_IN blood_NN and_CC noninvasive_JJ sites_NNS is_VBZ shown_VBN in_IN Table_NP ._SENT The_DT M_NP phenotype_NN was_VBD responsible_JJ for_IN 76_CD %_NN (_( 47_CD of_IN 62_CD )_) of_IN erythromycin_NN resistance_NN overall_JJ ,_, largely_RB due_JJ to_TO the_DT contribution_NN of_IN M_NP phenotype_NN ,_, serotype_NN 14_CD (_( M14_NP )_) isolates_NNS ,_, which_WDT accounted_VBD for_IN 60_CD %_NN (_( 37_CD of_IN 62_CD )_) of_IN all_DT resistant_JJ isolates_NNS and_CC 79_CD %_NN (_( 37_CD of_IN 47_CD )_) of_IN M_NP phenotype_NN resistance_NN ._SENT In_IN contrast_NN ,_, MLSB_NP isolates_NNS were_VBD responsible_JJ for_IN 24_CD %_NN (_( 15_CD of_IN 62_CD )_) of_IN erythromycin_NN resistance_NN and_CC were_VBD distributed_VBN across_IN serotypes_NNS 6_CD ,_, 14_CD ,_, 15_CD ,_, 19_CD ,_, and_CC 23_CD ._SENT The_DT M14_NP clone_NN was_VBD responsible_JJ for_IN 83_CD %_NN (_( 15_CD of_IN 18_CD )_) of_IN erythromycin_NN resistance_NN in_IN blood_NN isolates_NNS but_CC 50_CD %_NN (_( 22_CD of_IN 44_CD )_) of_IN resistance_NN in_IN isolates_NNS from_IN other_JJ sites_NNS ._SENT All_DT M14_NP isolates_NNS were_VBD penicillin_NN susceptible_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT If_IN we_PP assume_VBP that_IN the_DT distribution_NN of_IN resistance_NN phenotypes_NNS was_VBD the_DT same_JJ in_IN isolates_NNS which_WDT were_VBD not_RB available_JJ for_IN examination_NN as_IN in_IN those_DT that_WDT were_VBD ,_, then_RB 10_CD %_NN of_IN blood_NN isolates_NNS were_VBD M14_JJ (_( 16_CD of_IN 160_CD )_) compared_VBN with_IN 2.1_CD %_NN of_IN isolates_NNS from_IN noninvasive_JJ sites_NNS (_( 30_CD of_IN 1,435_CD )_) ._SENT Thus_RB ,_, the_DT M14_NP clone_NN was_VBD proportionately_RB 4.8_CD times_NNS more_RBR common_JJ in_IN blood_NN than_IN in_IN noninvasive_JJ sites_NNS ,_, and_CC this_DT difference_NN is_VBZ statistically_RB significant_JJ (_( P_NN <_SYM 0.001_CD by_IN the_DT chi-square_NN test_NN )_) ._SENT Resistance_NN genes_NNS in_IN erythromycin-resistant_JJ isolates_NNS ._SENT |_SYM All_NP M_NP phenotype_NN isolates_NNS and_CC one_CD erythromycin-susceptible_JJ isolate_NN from_IN blood_NN were_VBD PCR_NP positive_JJ for_IN the_DT mef(A)_JJ gene_NN ._SENT Sequence_NN analysis_NN revealed_VBD that_IN the_DT mef(A)_JJ gene_NN carried_VBN by_IN all_DT M14_NP isolates_VBZ and_CC by_IN one_CD isolate_NN of_IN serotype_NN 9_CD was_VBD 100_CD %_NN identical_JJ to_TO the_DT mef(A)_JJ sequence_NN originally_RB described_VBN for_IN S._NP pyogenes_NNS (_( GenBank_NP accession_NN number_NN )_) ,_, and_CC all_PDT these_DT isolates_NNS carried_VBD the_DT sequence_NN of_IN the_DT msr(A)_JJ homologue_NN found_VBN in_IN Tn1207.1_NP (_( GenBank_NP accession_NN number_NN )_) ._SENT All_DT isolates_NNS with_IN this_DT mef(A)_JJ sequence_NN were_VBD positive_JJ by_IN PCR_NP with_IN primers_NNS designed_VBN to_TO amplify_VB Tn1207.1_NP when_WRB inserted_VBN into_IN the_DT celB_NN gene_NN ._SENT All_DT remaining_VBG M_NN phenotype_NN isolates_VBZ of_IN serotypes_NNS 9_CD ,_, 19_CD ,_, and_CC 23_CD carried_VBD the_DT mef(E)_JJ sequence_NN originally_RB described_VBN for_IN S._NP pneumoniae_NP (_( GenBank_NP accession_NN number_NN )_) ._SENT These_DT isolates_VBZ all_DT carried_VBN mel_NN ,_, the_DT msr(A)_JJ homologue_NN found_VBN in_IN the_DT transposable_JJ element_NN mega_JJ (_( GenBank_NP accession_NN number_NN )_) ._SENT Isolates_NNS with_IN the_DT mega_JJ sequence_NN did_VBD not_RB produce_VB a_DT PCR_NP product_NN with_IN primers_NNS designed_VBN to_TO amplify_VB Tn1207.1_NP when_WRB inserted_VBN into_IN the_DT celB_NN gene_NN ._SENT All_DT MLSB_NP isolates_NNS were_VBD erm(B)_JJ positive_NN by_IN PCR_NP ._SENT Two_CD serotype_NN 19_CD noninvasive_JJ isolates_NNS ,_, included_VBN in_IN Table_NP as_IN MLSB_NP phenotype_NN isolates_NNS ,_, contained_VBN both_CC the_DT mef(E)_NN and_CC erm(B)_NN genes_NNS ._SENT Tetracycline_NN resistance_NN ._SENT |_SYM Tetracycline_NP resistance_NN is_VBZ commonly_RB associated_VBN with_IN the_DT MLSB_NP phenotype_NN ,_, since_IN the_DT tet(M)_NN and_CC erm(B)_NN genes_NNS are_VBP both_CC found_VBN on_IN the_DT Tn1545_NP transposon_NN ._SENT Fourteen_NN of_IN the_DT 15_CD MLSB_NP isolates_NNS were_VBD resistant_JJ to_TO tetracycline_NN and_CC were_VBD PCR_NP positive_JJ for_IN tet(M)_NN ._SENT Nine_CD of_IN these_DT 14_CD isolates_NNS were_VBD also_RB PCR_NP positive_NN for_IN int_NNS and_CC xis_NNS ,_, the_DT integrase_NN and_CC excisionase_NN genes_NNS commonly_RB associated_VBN with_IN Tn1545_NP ;_: 4_CD isolates_NNS were_VBD negative_JJ for_IN both_DT int_NNS and_CC xis_NNS ,_, and_CC 1_CD isolate_NN was_VBD positive_JJ only_RB for_IN xis_NNS ._SENT One_CD MLSB_NP isolate_NN of_IN serotype_NN 23_CD was_VBD susceptible_JJ to_TO tetracycline_NN ._SENT This_DT isolate_NN was_VBD positive_JJ for_IN tet(M)_NN by_IN PCR_NP ,_, but_CC sequence_NN analysis_NN of_IN the_DT PCR_NP product_NN demonstrated_VBD a_DT 10-bp_JJ deletion_NN from_IN base_NN 619_CD to_TO 628_CD (_( this_DT deletion_NN was_VBD also_RB found_VBN in_IN an_DT isolate_NN with_IN the_DT same_JJ phenotype_NN collected_VBN in_IN our_PP$ laboratory_NN in_IN 1997_CD )_) ._SENT The_DT tetracycline-susceptible_JJ isolate_NN was_VBD PCR_NP positive_JJ for_IN int_NNS and_CC xis_NNS ._SENT Six_CD M_NP phenotype_NN isolates_VBZ of_IN serotypes_NNS 19_CD (_( two_CD isolates_NNS )_) and_CC 23_CD (_( four_CD isolates_NNS )_) were_VBD also_RB tetracycline_NN resistant_NN and_CC were_VBD PCR_NP positive_JJ for_IN tet(M)_NN ,_, int_NNS ,_, and_CC xis_NNS ._SENT Erythromycin_NN MICs_NNS for_IN M_NP phenotype_NN isolates_NNS ._SENT |_SYM Erythromycin_NP MICs_NP for_IN all_DT resistant_JJ isolates_NNS were_VBD determined_VBN by_IN E-test_NN and_CC by_IN broth_NN microdilution_NN (_( NCCLS_NP )_) ._SENT By_IN broth_NN microdilution_NN ,_, median_JJ erythromycin_NN MICs_NNS were_VBD 12_CD mg/liter_NN (_( range_NN ,_, 8_CD to_TO 24_CD mg/liter_NN )_) for_IN 38_CD M_NP phenotype_NN isolates_VBZ with_IN the_DT mef(A)_JJ sequence_NN and_CC 4_CD mg/liter_NN (_( range_NN ,_, 2_CD to_TO 8_CD mg/liter_NN )_) for_IN 9_CD isolates_NNS with_IN the_DT mef(E)_JJ sequence_NN ._SENT By_IN E-test_NN ,_, median_JJ MICs_NNS were_VBD 20_CD mg/liter_NN (_( range_NN ,_, 12_CD to_TO 32_CD mg/liter_NN )_) for_IN 38_CD M_NP phenotype_NN isolates_VBZ with_IN the_DT mef(A)_JJ sequence_NN and_CC 3_CD mg/liter_NN (_( range_NN ,_, 2_CD to_TO 4_CD mg/liter_NN )_) for_IN 9_CD isolates_NNS with_IN the_DT mef(E)_JJ sequence_NN ._SENT The_DT difference_NN in_IN MICs_NP between_IN mef(A)_NN and_CC mef(E)_NN isolates_NNS was_VBD statistically_RB significant_JJ by_IN both_DT methods_NNS (_( P_NN <_SYM 0.001_CD by_IN the_DT Mann-Whitney_NP test_NN )_) ._SENT Comparison_NN with_IN isolates_NNS from_IN other_JJ geographical_JJ locations_NNS ._SENT |_SYM To_TO determine_VB whether_IN the_DT mef(A)_JJ sequence_NN found_VBN in_IN our_PP$ Scottish_JJ M14_NP isolates_NNS reflected_VBD a_DT local_JJ phenomenon_NN ,_, we_PP sequenced_VBD the_DT gene_NN in_IN M14_NP isolates_VBZ from_IN other_JJ locations_NNS ,_, three_CD from_IN the_DT south_NN of_IN England_NP ,_, two_CD from_IN Australia_NP ,_, and_CC one_CD from_IN Belgium_NP ._SENT All_DT six_CD isolates_NNS also_RB carried_VBD the_DT mef(A)_JJ sequence_NN ._SENT Erythromycin_NN MICs_NNS for_IN these_DT isolates_NNS by_IN E-test_NN were_VBD in_IN the_DT range_NN of_IN 12_CD to_TO 32_CD mg/liter_NN ,_, similar_JJ to_TO that_DT of_IN the_DT local_JJ M14_NP clone_NN ._SENT It_PP has_VBZ previously_RB been_VBN shown_VBN by_IN pulsed-field_JJ gel_NN electrophoresis_NN analysis_NN that_IN the_DT profiles_NNS of_IN our_PP$ Scottish_JJ M14_NP isolates_NNS are_VBP very_RB similar_JJ to_TO those_DT of_IN isolates_NNS from_IN the_DT south_NN of_IN England_NP ._SENT The_DT serotype_NN 14_CD isolates_NNS from_IN England_NP ,_, Australia_NP ,_, and_CC Belgium_NP have_VBP all_RB been_VBN previously_RB characterized_VBN by_IN MLST_NP as_IN ST9_NP and_CC belong_VB to_TO an_DT M_NP phenotype_NN clone_NN associated_VBN with_IN meningitis_NN in_IN the_DT United_NP Kingdom_NP ._SENT MLST_NP analysis_NN of_IN nine_CD representative_JJ isolates_NNS from_IN our_PP$ local_JJ M14_NP clone_NN confirmed_VBD that_IN they_PP were_VBD also_RB ST9_JJ ._SENT TABLE_NN 1_CD |_SYM Distribution_NN of_IN resistance_NN phenotypes_NNS and_CC serotypes_NNS in_IN erythromycin-resistant_JJ S._NP pneumoniae_NNS isolates_NNS collected_VBN from_IN blood_NN (_( n_NN =_SYM 160_CD )_) and_CC noninvasive_JJ sites_NNS (_( n_NN =_SYM 1,435_CD )_) TABLE_NP 2_CD |_SYM Distribution_NN of_IN resistance-related_JJ genes_NNS and_CC transposable_JJ elements_NNS in_IN erythromycin-resistant_JJ S._NP pneumoniae_NNS isolates_VBZ This_DT study_NN demonstrates_VBZ that_IN the_DT M_NP phenotype_NN is_VBZ the_DT commonest_JJS form_NN of_IN erythromycin_NN resistance_NN in_IN northeast_JJ Scotland_NP ,_, largely_RB due_JJ to_TO the_DT predominance_NN of_IN a_DT serotype_NN 14_CD clone_NN that_WDT has_VBZ been_VBN characterized_VBN by_IN MLST_NP as_IN ST9_NP ._SENT Thus_RB ,_, the_DT phenotypic_JJ pattern_NN of_IN erythromycin_NN resistance_NN observed_VBD in_IN the_DT United_NP Kingdom_NP is_VBZ closer_JJR to_TO that_DT of_IN the_DT United_NP States_NP than_IN to_TO that_DT of_IN other_JJ European_JJ countries_NNS ,_, with_IN M_NP phenotype_NN resistance_NN at_IN least_JJS three_CD times_NNS more_RBR prevalent_JJ than_IN MLSB_NP resistance_NN overall_NN ._SENT We_PP have_VBP demonstrated_VBN that_IN the_DT ST9_NP clone_NN is_VBZ 4.8_CD times_NNS more_RBR common_JJ in_IN blood_NN than_IN in_IN other_JJ sites_NNS and_CC is_VBZ therefore_RB more_RBR invasive_JJ than_IN the_DT average_JJ S._NP pneumoniae_NNS isolate_VBP ._SENT The_DT ST9_NP clone_NN has_VBZ also_RB been_VBN identified_VBN as_IN an_DT important_JJ cause_NN of_IN meningitis_NN throughout_IN the_DT United_NP Kingdom_NP ,_, and_CC this_DT clone_NN is_VBZ now_RB recognized_VBN as_IN a_DT cause_NN of_IN invasive_JJ disease_NN in_IN other_JJ countries_NNS ._SENT There_EX are_VBP many_JJ virulence_NN factors_NNS other_JJ than_IN the_DT capsule_NN involved_VBN in_IN the_DT pathogenesis_NN of_IN pneumococcal_JJ infection_NN ,_, and_CC there_EX is_VBZ evidence_NN that_IN particular_JJ strains_NNS of_IN pneumococci_NNS have_VBP a_DT predilection_NN for_IN blood_NN and_CC cerebrospinal_JJ fluid_NN ._SENT Further_JJR characterization_NN of_IN invasive_JJ clones_NNS such_JJ as_IN ST9_NP will_MD help_VB to_TO explain_VB this_DT process_NN and_CC may_MD in_IN the_DT future_JJ offer_NN targets_NNS for_IN treatment_NN or_CC prevention_NN of_IN invasive_JJ pneumococcal_JJ disease_NN ._SENT An_DT increase_NN in_IN the_DT expression_NN of_IN a_DT variant_JJ form_NN of_IN the_DT enzyme_NN glyceraldehyde-3-phosphate_NN dehydrogenase_NN (_( GAPDH_NP )_) in_IN our_PP$ M14_NP clone_NN ,_, now_RB known_VBN to_TO be_VB ST9_NP ,_, has_VBZ been_VBN demonstrated_VBN previously_RB ._SENT In_IN other_JJ species_NNS such_JJ as_IN S._NP pyogenes_NNS and_CC Staphylococcus_NN aureus_NN ,_, GAPDH_NP is_VBZ located_VBN in_IN the_DT cell_NN wall_NN and_CC is_VBZ associated_VBN with_IN virulence_NN ._SENT The_DT role_NN of_IN GAPDH_NP in_IN the_DT pathogenicity_NN of_IN the_DT ST9_NP clone_NN is_VBZ therefore_RB worthy_JJ of_IN further_JJR study_NN ._SENT The_DT mef(A)_JJ genes_NNS of_IN S._NP pneumoniae_NP and_CC S._NP pyogenes_NNS were_VBD found_VBN initially_RB to_TO be_VB different_JJ and_CC were_VBD designated_VBN mef(E)_NN and_CC mef(A)_NN ,_, respectively_RB ._SENT We_PP have_VBP shown_VBN that_IN an_DT unusual_JJ characteristic_NN of_IN the_DT ST9_NP clone_NN is_VBZ that_IN it_PP possesses_VBZ the_DT mef(A)_JJ sequence_NN normally_RB associated_VBN with_IN S._NP pyogenes_NNS ._SENT The_DT original_JJ S._NP pyogenes_JJ sequence_NN [_SYM mef(A)_NN ]_SYM was_VBD reported_VBN for_IN four_CD isolates_NNS of_IN S._NP pneumoniae_NNS from_IN Italy_NP ,_, and_CC more_RBR recently_RB it_PP has_VBZ been_VBN reported_VBN for_IN a_DT further_JJR 17_CD isolates_NNS ,_, also_RB from_IN Italy_NP ._SENT Conversely_RB ,_, there_EX is_VBZ a_DT report_NN of_IN the_DT original_JJ pneumococcal_JJ sequence_NN [_SYM mef(E)_NN ]_SYM in_IN a_DT single_JJ isolate_NN of_IN S._NP pyogenes_NNS ,_, and_CC we_PP have_VBP also_RB observed_VBN this_DT (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT survey_NN of_IN erythromycin-resistant_JJ viridans_NNS streptococci_NNS found_VBD the_DT mef(E)_JJ sequence_NN in_IN S._NP mitis_NN ,_, S._NP oralis_NP ,_, and_CC S._NP anginosus_NP ,_, while_IN the_DT mef(A)_JJ sequence_NN was_VBD found_VBN in_IN only_RB one_CD isolate_NN of_IN S._NP oralis_NNS ._SENT Thus_RB ,_, the_DT potential_NN for_IN the_DT spread_NN of_IN M_NP phenotype_NN resistance_NN in_IN S._NP pneumoniae_NNS is_VBZ increased_VBN by_IN the_DT widespread_JJ presence_NN of_IN the_DT mef(A)_JJ gene_NN in_IN other_JJ ,_, less_RBR pathogenic_JJ species_NNS ._SENT The_DT original_JJ characterization_NN of_IN Tn1207.1_NP showed_VBD that_IN it_PP was_VBD associated_VBN with_IN the_DT mef(A)_JJ sequence_NN ,_, and_CC our_PP$ data_NNS confirmed_VBD that_IN all_DT pneumococcal_JJ isolates_NNS with_IN the_DT S._NP pyogenes_NNS mef(A)_NN sequence_NN contained_VBN Tn1207.1_NP ._SENT In_IN contrast_NN ,_, the_DT nine_CD M_NP phenotype_NN isolates_VBZ with_IN the_DT pneumococcal_JJ mef(E)_NN sequence_NN contained_VBD the_DT mega_JJ insertion_NN element_NN ._SENT It_PP seems_VBZ likely_RB ,_, therefore_RB ,_, that_IN the_DT two_CD mef(A)_JJ sequences_NNS are_VBP associated_VBN with_IN different_JJ transposable_JJ elements_NNS ._SENT In_IN support_NN of_IN this_DT conclusion_NN ,_, Del_NP Grosso_NP et_FW al._FW have_VBP also_RB demonstrated_VBN an_DT association_NN between_IN mef(A)_JJ sequence_NN and_CC genetic_JJ element_NN in_IN six_CD Italian_JJ isolates_NNS ._SENT Our_PP$ results_NNS indicate_VBP that_IN the_DT erythromycin_NN MIC_NN for_IN pneumococci_NNS possessing_VBG mef(A)_NN together_RB with_IN the_DT associated_JJ transposable_JJ element_NN Tn1207.1_NN is_VBZ higher_JJR than_IN that_IN for_IN pneumococci_NNS possessing_VBG mef(E)_NN in_IN association_NN with_IN mega_JJ ._SENT Gay_NP and_CC Stephens_NP demonstrated_VBD that_IN in_IN the_DT transposable_JJ element_NN mega_JJ ,_, the_DT mef(E)_JJ gene_NN is_VBZ cotranscribed_VBN with_IN mel_NN ,_, the_DT msr(A)_JJ homologue_NN ._SENT In_IN staphylococci_NNS ,_, msr(A)_NN encodes_VBZ an_DT ATP-binding_NP cassette_NN that_WDT provides_VBZ energy_NN for_IN the_DT efflux_NN of_IN macrolides_NNS and_CC streptogramin_NP B._NP Thus_RB ,_, the_DT erythromycin_NN MIC_NN may_MD be_VB influenced_VBN not_RB only_RB by_IN the_DT Mef(A)_NP protein_NN but_CC also_RB by_IN the_DT actions_NNS of_IN the_DT MsrA_NP homologue_NN ._SENT Different_JJ sites_NNS of_IN insertion_NN in_IN the_DT genome_NN may_MD also_RB result_VB in_IN different_JJ rates_NNS of_IN transcription_NN ._SENT However_RB ,_, relatively_RB few_JJ of_IN our_PP$ isolates_NNS contained_VBD the_DT mef(E)_JJ gene_NN sequence_NN ,_, and_CC therefore_RB further_JJR studies_NNS are_VBP required_VBN to_TO confirm_VB the_DT MIC_JJ difference_NN ._SENT Resistance_NN to_TO tetracycline_NN is_VBZ a_DT common_JJ characteristic_NN of_IN the_DT MLSB_NP phenotype_NN because_IN the_DT erm(B)_NN and_CC tet(M)_NN genes_NNS can_MD be_VB found_VBN on_IN the_DT same_JJ transposon_NN ,_, Tn1545_NP ._SENT The_DT presence_NN of_IN both_DT resistance_NN genes_NNS erm(B)_NN and_CC mef(A)_NN in_IN MLSB_NP isolates_VBZ has_VBZ been_VBN described_VBN previously_RB ,_, and_CC these_DT isolates_NNS are_VBP expected_VBN to_TO be_VB resistant_JJ to_TO tetracycline_NN ._SENT In_IN contrast_NN ,_, mef(A)_NN in_IN M_NP phenotype_NN isolates_VBZ is_VBZ not_RB known_VBN to_TO be_VB linked_VBN to_TO tetracycline_NN resistance_NN ._SENT We_PP have_VBP shown_VBN that_IN M_NP phenotype_NN isolates_VBZ of_IN serotypes_NNS 19_CD and_CC 23_CD can_MD carry_VB the_DT tet(M)_JJ gene_NN and_CC other_JJ elements_NNS of_IN Tn1545_NP ,_, such_JJ as_IN int_NNS and_CC xis_NNS ,_, without_IN possessing_VBG the_DT erm(B)_JJ gene_NN ._SENT Similar_JJ findings_NNS were_VBD reported_VBN for_IN Spanish_JJ isolates_NNS ._SENT In_IN this_DT study_NN we_PP have_VBP identified_VBN a_DT 10-bp_JJ deletion_NN in_IN the_DT sequence_NN of_IN the_DT tet(M)_JJ gene_NN of_IN an_DT MLSB_NP isolate_NN that_WDT was_VBD susceptible_JJ to_TO tetracycline_NN ,_, relative_JJ to_TO the_DT tet(M)_JJ sequence_NN in_IN tetracycline-resistant_JJ isolates_NNS ._SENT Susceptibility_NN to_TO tetracycline_NN in_IN MLSB_NP isolates_VBZ has_VBZ been_VBN reported_VBN for_IN Spanish_JJ isolates_NNS ,_, but_CC these_DT isolates_NNS did_VBD not_RB possess_VB the_DT tet(M)_JJ gene_NN ._SENT Our_PP$ data_NNS show_VBP that_IN tetracycline_NN resistance_NN is_VBZ not_RB a_DT reliable_JJ guide_NN to_TO MLSB_NP phenotype_NN erythromycin_NN resistance_NN ,_, since_IN we_PP found_VBD both_DT M_NP phenotypes_NNS that_WDT were_VBD resistant_JJ to_TO tetracycline_NN and_CC MLSB_NN phenotypes_NNS that_WDT were_VBD susceptible_JJ to_TO tetracycline_NN ._SENT In_IN conclusion_NN ,_, the_DT present_JJ study_NN has_VBZ demonstrated_VBN the_DT clinical_JJ importance_NN in_IN our_PP$ region_NN of_IN an_DT M_NP phenotype_NN ,_, serotype_NN 14_CD clone_NN of_IN S._NP pneumoniae_NNS that_WDT has_VBZ invasive_JJ properties_NNS and_CC for_IN which_WDT MICs_NNS are_VBP higher_JJR than_IN for_IN other_JJ M_NP phenotype_NN isolates_NNS ._SENT The_DT clone_NN has_VBZ been_VBN identified_VBN as_IN ST9_NP and_CC has_VBZ been_VBN isolated_VBN in_IN other_JJ parts_NNS of_IN the_DT world_NN ._SENT Further_JJR characterization_NN of_IN this_DT clone_NN may_MD yield_VB further_JJR insights_NNS into_IN both_DT invasiveness_NN and_CC the_DT detailed_JJ mechanisms_NNS of_IN M_NP phenotype_NN resistance_NN ._SENT 